Retatrutide (Research-Grade Peptide)

Investigational triple agonist (GIP/GLP-1/Glucagon) — for laboratory research only

Product Overview

Retatrutide (also known as LY3437943) is a synthetic peptide designed to agonize three metabolic hormone receptors:
glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and the glucagon receptor (GCGR).
This multi-receptor approach is being investigated in preclinical and clinical research for its effects on body-weight
regulation, glycemic control, and liver fat. Supplied as high-purity lyophilized powder, this material is intended strictly
for research use and not for human or veterinary administration.

Research Highlights

• Triple-Receptor Mechanism: Retatrutide activates GLP-1, GIP, and glucagon receptors in a single peptide, a strategy shown to support glucose control and weight loss in early studies.
  Cell Metabolism (2022),
  The Lancet (Phase 1)
• Obesity (Phase 2) Data: In a 48-week randomized trial in adults with obesity/overweight, the highest retatrutide dose achieved a mean body-weight reduction of ~24.2% at week 48, with substantial reductions by week 24.
  NEJM (2023),
  Lilly summary
• Type 2 Diabetes Research: Early-phase trials reported clinically meaningful glucose-lowering and weight effects, supporting once-weekly dosing regimens for further study.
  The Lancet (2022)
• MASLD/NAFLD Sub-Study: In participants with metabolic dysfunction-associated steatotic liver disease, retatrutide reduced liver fat at 24 weeks (dose-dependent), with a high proportion reaching normal liver fat on higher doses.
  Nature Medicine (2024)

Product Details & Handling

• Synonyms: Retatrutide; LY3437943
• Form: Lyophilized powder, supplied in sterile vials
• Purity: ≥ 98% (Certificate of Analysis provided)
• Storage: Store at –20 °C; protect from light and moisture
• Handling: Use only in controlled laboratory settings with appropriate PPE; consult SDS for detailed safety information

Legal Disclaimer

This product is provided strictly for laboratory research use only.
It is not intended for human or veterinary consumption, therapeutic, diagnostic, or clinical application.
Customers are responsible for compliance with all applicable laws and institutional policies.
Retatrutide is an investigational compound not approved by the FDA as a drug, supplement, or treatment.
Windy City Peptide does not provide medical advice or support related to human use.